Rohtak News Magazine

European Biosimilar Market Share 2022: Global Industry Size, Growth, Opportunity, Key Players and Trends 2027

 Breaking News
  • No posts were found

European Biosimilar Market Share 2022: Global Industry Size, Growth, Opportunity, Key Players and Trends 2027

August 26
17:00 2022
 European Biosimilar Market Share 2022: Global Industry Size, Growth, Opportunity, Key Players and Trends 2027
Looking forward, IMARC Group expects the market to reach US$ 25,446 Million by 2027, exhibiting at a CAGR of 22.8% during 2022-2027

The latest report by IMARC Group, titled “Biosimilar Market in Europe: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027.’ Offers a comprehensive analysis of the industry, which comprises insights on European Biosimilar Market Share

The biosimilar market in Europe reached a value of US$ 6,735 Million in 2021. Looking forward, IMARC Group expects the market to reach US$ 25,446 Million by 2027, exhibiting at a CAGR of 22.8% during 2022-2027.Biosimilars, also called subsequent entry biologics (SEBs), refer to medical products that are similar to reference biologics in terms of their quality, efficacy, safety, etc. They are generally produced from living organisms, including yeast, animal or plant cells, bacteria, etc., and have a complex molecular structure. In addition to this, biosimilars are manufactured under the guidance of licensed facilities that are considered as an essential part of post-market surveillance. As such, they are extensively utilized in the production of therapeutic proteins, vaccines, monoclonal antibodies, etc. 

Download a free sample report to get a detailed overview of the report: https://www.imarcgroup.com/europe-biosimilar-market/requestsample

Market Trends:

The growing investments in the field of medical science and biotechnology are primarily driving the Europe biosimilar market. Moreover, the expanding geriatric population and the increasing prevalence of autoimmune diseases, cancer, diabetes, etc., owing to the sedentary lifestyle patterns of individuals, are also positively influencing the regional market. Apart from this, the launch of numerous favorable policies by government bodies and third-party payers in Europe to upgrade the existing healthcare infrastructures and the patent expiration of various blockbuster biologics are acting as significant growth-inducing factors. Furthermore, the development of state-of-the-art technology for comparing the characteristics, including chemical identity, purity, bioactivity, etc., of the proposed biosimilars to their reference product is stimulating the market growth. Besides this, the inflating need for safe and affordable alternatives to originator biological therapies is projected to fuel the Europe biosimilar market in the coming years.

Checkout Now: https://www.imarcgroup.com/checkout?id=2073&method=1

As the novel coronavirus (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the industry behaviors of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.

Report Features

Details

Base Year of the Analysis

2021

Historical Period

2016-2021

Forecast Period

2022-2027

Units

US$ Million

Segment Coverage

Molecule, Indication, Manufacturing Type, Country

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the biosimilar market in Europe, along with forecasts at the regional and country level from 2022-2027. Our report has categorized the market based on molecule, indication and manufacturing type.

Some of the leading players operating in the European biosimilars market include:

  • Novartis
  • Pfizer
  • Teva 
  • Celltrion 
  • Samsung Bioepis 
  • Amgen
  • Apotex 
  • Ratiopharm
  • Mylan
  • Merck Sharp & Dohme
  • Eli Lilly
  • Accord Healthcare Ltd
  • Boehringer Ingelheim
  • Hexal Ag 
  • Stada Arzneimittel Ag

Breakup by Molecule

  • Infliximab
  • Insulin Glargine
  • Epoetin Alfa
  • Etanercept
  • Filgrastim
  • Somatropin
  • Rituximab
  • Follitropin Alfa
  • Adalimumab

Breakup by Indication

  • Auto-Immune Diseases
  • Blood Disorder
  • Diabetes
  • Oncology
  • Growth Deficiency
  • Female Infertility

Breakup by Manufacturing Type

  • In-house Manufacturing
  • Contract Manufacturing

Breakup by Country:

  • Italy
  • Germany
  • United Kingdom
  • France
  • Spain
  • Others

Ask Analyst for 10% free customized report: https://www.imarcgroup.com/europe-biosimilar-market

Note: We are updating our reports, If you want the report with the latest primary and secondary data (2022-2027) including industry trends, market size and Competitive landscape, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours.

Key highlights of the report:                                                           

  • Market Performance (2016-2021)
  • Market Outlook (2022-2027)
  • Market Trends
  • Market Drivers and Success Factors
  • Impact of COVID-19
  • Value Chain Analysis
  • Comprehensive mapping of the competitive landscape

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

Sources:

North America Active Pharmaceutical Ingredient Market

Asia Pacific Biodiesel Market

North America Glue Laminated Timber Market

Asia Pacific Footwear Market

Medical Textiles Market

Warship and Naval Vessels Market 

Mining Truck Market 

Atrial Fibrillation Treatment Market

Internet Protocol Television Market

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

Media Contact
Company Name: IMARC Group
Contact Person: Elena Anderson
Email: Send Email
Phone: +1-631-791-1145
Address:30 N Gould St Ste R
City: Sheridan
State: WY
Country: United States
Website: https://www.imarcgroup.com

Related Articles